Anti-Cancer Drugs Market by Drug Class (Chemotherapy, Targeted Therapy (Monoclonal Antibodies, Small Molecule Inhibitors), Immunotherapy, Hormone Therapy & Others), by Dosage Form (Solid (Tablets, Capsule), Liquid, Injectable (Prefilled Syringes, Others) & Others), by Route of Administration (Oral, Parenteral & Others), by Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer & Others), by End Use (Hospital, Speciality Clinics, Research Centers & Others), by Distribution Channels (Hospital, Retail Pharmacy, Online Pharmacy & Others) - Global Opportunity Analysis & Industry Forecast, 2022-2027

Report Code: HCR 0965 Report Format: PDF + Excel

Anti-Cancer Drugs Market Overview

Anti-Cancer Drugs Market Size is estimated to reach $211.4 billion by 2027 and is poised to grow at a CAGR of 7.2% over the forecast period of 2022-2027. The medication that is used for treating malignant or cancerous disease is referred to as an anticancer drug, often known as an antineoplastic drug. Alkylating agents, antimetabolites, natural products and hormones are a few of the main groups of anticancer medications. There are many types of cancer such as Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer and others. To treat the different types of cancer, different drugs are used alone or in combination. Cancer can be treated with chemotherapy, targeted therapy, immunotherapy, hormone therapy and others; which depends on the type and stage of cancer. World Health Organisation (WHO) estimates the number of new cases of cancer rise from 18.1 million in 2018 to 29.4 million by 2040. Owing to such increasing prevalence of cancer, the demand for anti-cancer drug is very high in the market. Such growing demand and increasing prevalence rate drive the growth of the Anti-Cancer Drugs Market over the forecast period 2022-2027.

Anti-Cancer Drugs Market Report Coverage

The report: “Anti-Cancer Drugs Market Forecast (2022-2027)" by IndustryARC, covers an in-depth analysis of the following segments in the Anti-Cancer Drugs Market.

by Drug Class: Chemotherapy, Targeted Therapy (Monoclonal Antibodies, Small Molecule Inhibitors), Immunotherapy, Hormone Therapy and Others.
by Dosage Form: Solid (Tablets, Capsule), Liquid, Injectable (Prefilled Syringes, Others) and Others. 
by Route of Administration: Oral, Parenteral and Others.
by Indication: Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Others.
by End Use: Hospital, Speciality Clinics, Research Centers and Others.
by Distribution Channels: Hospital, Retail Pharmacy, Online Pharmacy and Others.
by Geography: North America (the US, Canada and Mexico), Europe (Germany, the UK, France, Italy, Spain, Russia and the Rest of Europe), Asia-pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia-pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021, owing to the growing research and developments for the production of new cancer treatments which drive the Anti-Cancer Drugs Market Size.
  • The Anti-Cancer Drugs Market is predicted to grow owing to the increasing prevalence of cancer around the world.
  • However, the expiring patents of many drugs may limit the Anti-Cancer Drugs Industry growth over the forecast period 2022-2027.
  • A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Anti-Cancer Drugs Market Report.

Anti-Cancer Drugs Market: Market Share (%) by region, 2021

For More Details on This Report - Request for Sample

Anti-Cancer Drugs Market Segment Analysis- by Drug Class

Anti-Cancer Drugs Market based on the drug class can be further segmented into Chemotherapy, Targeted Therapy (Monoclonal Antibodies and Small Molecule Inhibitors), Immunotherapy, Hormone Therapy and others. The Chemotherapy segment held a dominant market share in 2021. This is due to the action of chemotherapy treatment which targets cells at different phases of the cell cycle. Alkylating agents, nitrosoureas, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, corticosteroids and other chemotherapy drugs are used to treat cancer. Such use of chemotherapy in cancer drives the growth of the Anti-Cancer Drugs Market share. However, Targeted Therapy is estimated to grow with the fastest CAGR of 7.9% over the forecast period 2022-2027. This is attributed to the benefits of targeted therapy which interferes with specific proteins involved in tumorigenesis focusing on specific molecular changes which are unique to particular cancer. Also, the high success rate of targeted therapy, which is about 80%, increases the demand for cancer treatment and drives the growth of the Anti-Cancer Drugs Market share over the forecast period 2022-2027.

Anti-Cancer Drugs Market Segment Analysis - by Indication

Anti-Cancer Drugs Market based on the indication can be further segmented into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other types of Cancers. The Breast cancer segment held a dominant market share in 2021, owing to the growing prevalence of breast cancer in the world. As per WHO, in 2020 about 2.3 million women were diagnosed with breast cancer and 685,000 deaths globally. Such a high prevalence of breast cancer surge demand for treatment and drive the growth of the Anti-Cancer Drugs Market share. However, Lung cancer is estimated to grow with the fastest CAGR of 8.3% over the forecast period 2022-2027. Lung cancer is the second most common cancer around the world and about 2.2 million new cancer cases were reported in 2020. Smoking and radon exposure are leading causes of lung cancer. Such growing cases of lung cancer fuel the growth of the Anti-Cancer Drugs Market Share over the forecast period 2022-2027.

Anti-Cancer Drugs Market Segment Analysis - by Geography

The Anti-Cancer Drugs Market based on Geography can be further segmented into North America, Europe, Asia-pacific, South America and the Rest of the World. North America held a dominant market share of 34% in the year 2021. This is the result of the increasing prevalence of cancer in this region. In 2022, there would be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Such a high prevalence of cancer in this region drives the growth of the Anti-Cancer Drugs Market Size. Furthermore, Asia-pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. In Asia-pacific, the most common cancers in men are lung, stomach, liver, colorectal and oesophageal cancers while the most common cancers in women are breast, lung, cervical, colorectal and stomach cancers. Also, the growing clinical research and increasing investment in healthcare infrastructure fuel the growth of the Anti-Cancer Drugs Market Size over the forecast period 2022-2027.

Anti-Cancer Drugs Market Drivers

New Innovative Drug Launches Drives Market Growth:

Owing to increasing demand for cancer drugs, key manufacturers launched new innovative drugs in the market. In May 2022, Roche Pharma launched PHESGO, the first ever fixed-dose formulation in oncology for breast cancer. In 2022, there would be approximately 4,820,000 new cancer cases and 3,210,000 cancer deaths in China and breast cancer is one of the leading types of cancer found in women in China. Such increasing prevalence of cancer and new innovative products launched by leading market players drive the growth of the Anti-Cancer Drugs Industry over the forecast period 2022-2027.

Growing Investment in Healthcare Infrastructure Drives Market Growth:

Owing to the high possibility of cancer, various governments and organizations focus on developing better healthcare infrastructure to provide essential health services to people. In November 2021, Union Health Minister announced that the central government would invest INR 64 crore in the country’s healthcare infrastructure. Such growing investment to strengthen the investment drives the growth of the Anti-Cancer Drugs Industry over the forecast period 2022-2027.

Anti-Cancer Drugs Market Challenge

Generic Drugs Are Hampering Market Growth:

For making cancer treatment affordable, various governments gave permission to use generic drugs for the treatment of cancer. As per the European Pharmaceutical Review in February 2021, there were about 1,351 generic drugs available for cancer treatment in India. Such availability of generic drugs may limit the growth of the Anti-Cancer Drugs Industry growth over the forecast period 2022-2027.

Anti-Cancer Drugs Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Anti-Cancer Drugs Market. The top 10 companies in the Anti-Cancer Drugs Market are:

  1. F. Hoffmann-La Roche Ltd.
  2. Roche Holding AG
  3. Celgene Corp
  4. Novartis AG
  5. Bristol-Myers Squibb Co.
  6. Johnson & Johnson
  7. Merck & Co.
  8. Eli Lilly and Company
  9. AstraZeneca plc.
  10. Amgen Inc.

Recent Developments

  • In April 2022, Novartis announced the (FDA) granted commercial licensure approval for its Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the 170,000 square-foot facilities to make, test and release commercial Zolgensma, as well as produce gene therapy products for current and future clinical trials.
  • In June 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement for the acquisition of Turning Point Therapeutics. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis.
  • In October 2021, Amgen announced the successful completion of its previously announced acquisition of Teneobio, Inc. by cash payment of $900 million. The acquisition included Teneobio's proprietary bispecific and multispecific antibody technologies.

Relevant Titles

Personalized Medicines in Oncology Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0097

Oncology Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 1226

Anti-neoplastic Therapy Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 1256 

For more Lifesciences and Healthcare Market reports, please click here

1. Anti-Cancer Drugs Market - Overview
    1.1 Definitions and Scope
2. Anti-Cancer Drugs Market - Executive Summary
3. Anti-Cancer Drugs Market - Comparative Analysis
    3.1 Company Benchmarking – Key Companies
    3.2 Global Financial Analysis – Key Companies
    3.3 Market Share Analysis – Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Anti-Cancer Drugs Market - Start-up Companies Scenario Premium
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Anti-Cancer Drugs Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Anti-Cancer Drugs Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porter's Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Anti-Cancer Drugs Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Anti-Cancer Drugs Market – by Drug Class
    8.1 Chemotherapy
    8.2 Targeted Therapy
        8.2.1 Monoclonal Antibodies
        8.2.2 Small Molecule Inhibitors
    8.3 Immunotherapy
    8.4 Hormonal Therapy
    8.5 Others
9. Anti-Cancer Drugs Market – by Dosage Form
    9.1 Solid
        9.1.1 Tablets
        9.1.2 Capsule
    9.2 Liquid
    9.3 Injectable
        9.3.1 Prefilled Syringes
        9.3.2 Others
    9.4 Others
10. Anti-Cancer Drugs Market – by Route of Administration
    10.1 Oral
    10.2 Parenteral
    10.3 Others
11. Anti-Cancer Drugs Market – by Indication 
    11.1 Lung Cancer
    11.2 Stomach Cancer
    11.3 Colorectal Cancer
    11.4 Breast Cancer
    11.5 Prostate Cancer
    11.6 Liver Cancer
    11.7 Esophagus Cancer
    11.8 Cervical Cancer
    11.9 Kidney Cancer
    11.10 Bladder Cancer
    11.11 Others
12. Anti-Cancer Drugs Market – by End-use
    12.1 Hospital
    12.2 Speciality Clinics
    12.3 Research Centers
    12.4 Others
13. Anti-Cancer Drugs Market – by Distribution Channel
    13.1 Hospital Pharmacy
    13.2 Retail Pharmacy
    13.3 Online Pharmacy
    13.4 Others
14. Anti-Cancer Drugs Market - by Geography
    14.1 North America
        14.1.1 The US
        14.1.2 Canada
        14.1.3 Mexico
    14.2 Europe
        14.2.1 The UK
        14.2.2 Germany
        14.2.3 France
        14.2.4 Italy
        14.2.5 Spain
        14.2.6 Russia
        14.2.7 The Rest of Europe
    14.3 Asia-pacific
        14.3.1 China
        14.3.2 India
        14.3.3 Japan
        14.3.4 South Korea
        14.3.5 Australia & New Zealand
        14.3.6 The Rest of Asia-pacific
    14.4 South America
        14.4.1 Brazil
        14.4.2 Argentina
        14.4.3 Chile
        14.4.4 Colombia
        14.4.5 The Rest of South America
    14.5 The Rest of the World
        14.5.1 The Middle East
        14.5.2 Africa
15. Anti-Cancer Drugs Market - Entropy
16. Anti-Cancer Drugs Market – Industry/Segment Competition Landscape Premium 
    16.1 Market Share Analysis
        16.1.1 Market Share by Region – Key companies
        16.1.2 Market Share by Countries – Key Companies
    16.2 Competition Matrix
    16.3 Best Practices for Companies
17. Anti-Cancer Drugs Market – Key Company List by Country Premium Premium
18. Anti-Cancer Drugs Market - Company Analysis
    18.1 Company 1
    18.2 Company 2
    18.3 Company 3
    18.4 Company 4
    18.5 Company 5
    18.6 Company 6
    18.7 Company 7
    18.8 Company 8
    18.9 Company 9
    18.10 Company 10
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.